期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Pax8-PPARγ1与甲状腺滤泡状癌的研究进展 被引量：2

Research Progress in Pax8-PPARγ1 and Follicular Thyroid Carcinoma
原文传递
导出
摘要 甲状腺癌是内分泌系统中最常见的恶性肿瘤,约占全身恶性肿瘤的1%￣2%。其中滤泡状癌约占甲状腺癌的10%￣30%。在相当一部分甲状腺滤泡状癌中存在染色体t(2;3)(q13;p25)易位,形成融合基因Pax8-PPARγ1。文章综述该融合基因在致癌机制、与甲状腺肿瘤的鉴别诊断以及预后和基因治疗等方面的研究进展。
作者 蒋华锋 赵文和
机构地区 浙江大学医学院附属第一医院
出处 《肿瘤学杂志》 CAS 2008年第9期763-766,共4页 Journal of Chinese Oncology
关键词 甲状腺肿瘤 Pax8-PPARγ1融合基因 EGFR
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Lang BH, Lo CY, Chan WF, et al. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre[J]. Endocr Relat Cancer, 2007, 14(1):29-42.
  • 2Au AY, McBride C, Wilhelm KG Jr, et al. PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth [J]. Endocrinology, 2006, 147(1):367-376.
  • 3Giordano TJ, Au AY, Kuick R, et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8- PPARG translocation[J]. Clin Cancer Res, 2006, 12(7 Pt 1):1983-1993.
  • 4Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgammal fusion oncogene in human thyroid carcinoma [corrected][J]. Science, 2000, 289(5483):1357-1360.
  • 5Nikiforova MN,Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma [J]. J Clin Endocrinol Metab, 2003, 88(5):2318-2326.
  • 6Foukakis T, Au AY, Wallin G, et al. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAXS-PPAR gamma fnsion [J]. J Clin Endocrinol Metab, 2006, 91(3):1143-1149.
  • 7Reddi HV, Mclver B, Grebe SK, et al. The paired box-8/ peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis[J]. Endocrinology, 2007, 148(3): 932-935.
  • 8Lacroix L, Lazar V, Michiels S, et al. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations [J]. Am J Pathol, 2005, 167(1):223-231.
  • 9Lui WO, Foukakis T, Liden J, et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene[J]. Oncogene, 2005, 24(8):1467-1476.
  • 10Di Cristofaro J, Silvy M, Lanteaume A, et al. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes[J]. Endocr Relat Cancer, 2006, 13(2):485-495.

同被引文献37

  • 1郑荣秀,方佩华,吕枚.甲状腺乳头状癌患者ret基因重排突变[J].中华内分泌代谢杂志,2005,21(2):106-109. 被引量：9
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J].CA Cancer J Clin, 2013, 63 ( 1 ) : 11-30.
  • 3Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis [J]. Lancet, 2002,360(9340) : 1131-1135.
  • 4Durante C, Haddy N, Baudin E, et al. Longterm outcome of 444 patients with distant metastases from papillary and follicular thy- roid carcinoma: benefits and limits of radioiodine therapy [J]. J Clin Endocrinol Metab, 2006,91 ( 8 ) : 2892-2899.
  • 5Kerbel RS. Tumor angiogenesis [J]. N Engl J Med, 2008, 358 (19) : 2039-2049.
  • 6Agrawal N, Akbani R, Aksoy B, et al. Integrated genomic char- acterization of papillary thyroid carcinoma [J]. Cell, 2014, 159 (3) :676-690.
  • 7Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CAalterations in a Middle Eastern population [J]. J Clin Endocrinol Metab, 2008,93 (2) : 611-618.
  • 8Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/ PTC rearrangements in thyroid papillary carcinomas: effects of thedetection methods and genetic heterogeneiiy [ J ]. J Clin Endo- crinol Metab, 2006,91 (9) : 3603-3610.
  • 9Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas [J]. J Clin Endocrinol Metab, 2002, 87(8) :3947-3952.
  • 10Wilhelm SM, Carter C, Tang L. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progres- sion and angiogenesis [J]. Cancer Res, 2004, 64 (19) : 7099- 7109.

引证文献2

二级引证文献8

肿瘤学杂志
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部